



Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies

August 23, 2018

--Achieves #1 ranking for both 3-year EPS and revenue growth--

WOODCLIFF LAKE, N.J.--([BUSINESS WIRE](#))--Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that the Company has been named to the Fortune 100 List of Fastest-Growing Companies, ranking 16th overall, including achieving the #1 positions for EPS 3-year growth of 392% and revenue 3-year growth of 109%.

"We are extremely proud of how our team has executed on our overall growth strategy. We continue to see excellent opportunities ahead for our business," stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.

Fortune's list ranks public companies, with market capitalization of \$250 million or more, based on revenue growth rate, EPS growth rate and three-year annualized total return for the period ended June 30, 2018.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle's strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company's website at www.eagleus.com.

Forward-Looking Statements

This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as "will," "continue," "may," "believe," "intends," "anticipate(s)," "plan," "enables," "potentially," "entitles," and similar expressions are intended to identify forward-looking statements. These statements include statements regarding future events including, but not limited to: Eagle's ability to defend against third party attempts to design around or invalidate its patents; successful compliance with FDA and other governmental regulations applicable to product approval, manufacturing facilities, products and/or businesses; the FDA's ability to approve any drug applications referencing BENDEKA prior to December 2022; the ability of generic TREANDA products to enter the market prior to 2022; Eagle's market protection for BENDEKA; the commercial success of Eagle's commercial portfolio, including BENDEKA; successful compliance with FDA and other governmental regulations; the ability of Eagle to deliver sustained shareholder value over time; and other factors that are discussed in Eagle's Annual Report on Form 10-K for the year ended December 31, 2017, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle's control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to whether Eagle's management and/or board of directors will be effective in managing Eagle's business and future growth, as well as the other risks described in Eagle's filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson, 212-452-2793
lwilson@insitecony.com